Elevation of Serum Lactate Dehydrogenase in AL Amyloidosis Reflects Tissue Damage and is an Adverse Prognostic Marker in Patients Not Eligible for Stem Cell Transplantation

Overview

Journal Br J Haematol

Specialty Hematology

Date 2017 Jul 13

PMID 28699650

Citations 7

Authors

Eli Muchtar

Angela Dispenzieri

Martha Q Lacy

Francis K Buadi

Prashant Kapoor

Suzanne R Hayman

Wilson Gonsalves

Rahma Warsame

Taxiarchis V Kourelis

Rajshekhar Chakraborty

Stephen Russell

John A Lust

Yi Lin

Ronald S Go

Steven Zeldenrust

David Dingli

Nelson Leung

S Vincent Rajkumar

Robert A Kyle

Shaji K Kumar

Morie A Gertz

Affiliations

Soon will be listed here.

Abstract

The significance of serum lactate dehydrogenase (LDH) in light chain (AL) amyloidosis has not been previously explored. We studied 1019 newly diagnosed patients and correlated the elevation of LDH above the upper limit of normal (ULN) with disease characteristics and outcome. Four hundred and nine patients had an LDH above ULN, representing 40% of the study population. Patients with an elevated LDH were older, were less likely to be male and had more extensive organ involvement compared to patients with a normal LDH. Patients with high LDH had greater cardiac and renal dysfunction. Elevated LDH was an independent prognostic marker for overall survival and for death within 6 months of diagnosis, but this was restricted to patients not eligible for stem cell transplant. Serum LDH may act as a marker for organ damage and should be explored as a potential marker for tissue healing and organ recovery.

Citing Articles

Pre-and Post-Transplant Serum Lactate Dehydrogenase Levels as a Predictive Marker for Patient Survival and Engraftment in Allogeneic Hematopoietic Stem Cell Transplant Recipients.

Roshandel E, Parkhideh S, Ghaffari Nazari H, Mehdizadeh M, Bonakchi H, Sankanian G Rep Biochem Mol Biol. 2021; 10(2):204-215.

PMID: 34604410 PMC: 8480290. DOI: 10.52547/rbmb.10.2.204.

Knockdown of miR-1275 protects against cardiomyocytes injury through promoting neuromedin U type 1 receptor.

Zeng Z, Ma H, Chen J, Huang N, Zhang Y, Su Y Cell Cycle. 2020; 19(24):3639-3649.

PMID: 33323026 PMC: 7781665. DOI: 10.1080/15384101.2020.1860310.

Right Heart Changes Impact on Clinical Phenotype of Amyloid Cardiac Involvement: A Single Centre Study.

Cicco S, Solimando A, Buono R, Susca N, Inglese G, Melaccio A Life (Basel). 2020; 10(10).

PMID: 33081052 PMC: 7603245. DOI: 10.3390/life10100247.

Clinical Factors Associated with Progression and Prolonged Viral Shedding in COVID-19 Patients: A Multicenter Study.

Feng Z, Li J, Yao S, Yu Q, Zhou W, Mao X Aging Dis. 2020; 11(5):1069-1081.

PMID: 33014523 PMC: 7505267. DOI: 10.14336/AD.2020.0630.

MAGE genes: Prognostic indicators in AL amyloidosis patients.

Liu Y, Wen L, Ma L, Kang Y, Liu K, Huang X J Cell Mol Med. 2019; 23(8):5672-5678.

PMID: 31222935 PMC: 6653474. DOI: 10.1111/jcmm.14475.

References

Huang X, Wang Q, Jiang S, Chen W, Zeng C, Liu Z . The clinical features and outcomes of systemic AL amyloidosis: a cohort of 231 Chinese patients. Clin Kidney J. 2015; 8(1):120-6. PMC: 4310422. DOI: 10.1093/ckj/sfu117. View

Merlini G, Seldin D, Gertz M . Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol. 2011; 29(14):1924-33. PMC: 3138545. DOI: 10.1200/JCO.2010.32.2271. View

Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst H, Goldschmidt H, Rosinol L . Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015; 33(26):2863-9. PMC: 4846284. DOI: 10.1200/JCO.2015.61.2267. View

Warsame R, Kumar S, Gertz M, Lacy M, Buadi F, Hayman S . Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death. Blood Cancer J. 2015; 5:e310. PMC: 4423220. DOI: 10.1038/bcj.2015.34. View

GLICK Jr J . Serum lactate dehydrogenase isoenzyme and total lactate dehydrogenase values in health and disease, and clinical evaluation of these tests by means of discriminant analysis. Am J Clin Pathol. 1969; 52(3):320-8. DOI: 10.1093/ajcp/52.3.320. View

Comenzo R, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H . Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia. 2012; 26(11):2317-25. DOI: 10.1038/leu.2012.100. View

Kumar S, Dispenzieri A, Lacy M, Hayman S, Buadi F, Colby C . Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012; 30(9):989-95. PMC: 3675680. DOI: 10.1200/JCO.2011.38.5724. View

Walenta S, Mueller-Klieser W . Lactate: mirror and motor of tumor malignancy. Semin Radiat Oncol. 2004; 14(3):267-74. DOI: 10.1016/j.semradonc.2004.04.004. View

Kourelis T, Kumar S, Gertz M, Lacy M, Buadi F, Hayman S . Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. J Clin Oncol. 2013; 31(34):4319-24. PMC: 4881366. DOI: 10.1200/JCO.2013.50.8499. View

10.

Muchtar E, Dispenzieri A, Kumar S, Buadi F, Lacy M, Zeldenrust S . Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. Leukemia. 2016; 31(1):92-99. DOI: 10.1038/leu.2016.140. View

11.

Danese E, Montagnana M . An historical approach to the diagnostic biomarkers of acute coronary syndrome. Ann Transl Med. 2016; 4(10):194. PMC: 4885896. DOI: 10.21037/atm.2016.05.19. View

12.

Gkotzamanidou M, Kastritis E, Gavriatopoulou M, Nikitas N, Gika D, Mparmparousi D . Increased serum lactate dehydrongenase should be included among the variables that define very-high-risk multiple myeloma. Clin Lymphoma Myeloma Leuk. 2011; 11(5):409-13. DOI: 10.1016/j.clml.2011.07.001. View

13.

Miles R, Arnold S, Cairo M . Risk factors and treatment of childhood and adolescent Burkitt lymphoma/leukaemia. Br J Haematol. 2012; 156(6):730-43. DOI: 10.1111/j.1365-2141.2011.09024.x. View

14.

Muchtar E, Gertz M, Kumar S, Lacy M, Dingli D, Buadi F . Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood. 2017; 129(15):2111-2119. PMC: 5391625. DOI: 10.1182/blood-2016-11-751628. View

15.

Winter J . Prognostic markers in diffuse large B-cell lymphoma: Keys to the underlying biology. Curr Hematol Malig Rep. 2010; 2(4):235-41. DOI: 10.1007/s11899-007-0032-0. View

16.

Bochtler T, Hegenbart U, Kunz C, Granzow M, Benner A, Seckinger A . Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens. J Clin Oncol. 2015; 33(12):1371-8. DOI: 10.1200/JCO.2014.57.4947. View

17.

Wulaningsih W, Holmberg L, Garmo H, Malmstrom H, Lambe M, Hammar N . Serum lactate dehydrogenase and survival following cancer diagnosis. Br J Cancer. 2015; 113(9):1389-96. PMC: 4815785. DOI: 10.1038/bjc.2015.361. View

18.

Muchtar E, Dispenzieri A, Kumar S, Ketterling R, Dingli D, Lacy M . Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category. Leukemia. 2016; 31(7):1562-1569. DOI: 10.1038/leu.2016.369. View

19.

Gallo M, Sapio L, Spina A, Naviglio D, Calogero A, Naviglio S . Lactic dehydrogenase and cancer: an overview. Front Biosci (Landmark Ed). 2015; 20(8):1234-49. DOI: 10.2741/4368. View

20.

Gertz M, Kyle R, Greipp P . The plasma cell labeling index: a valuable tool in primary systemic amyloidosis. Blood. 1989; 74(3):1108-11. View